Helv Chim Act final version 21121 resubmitted.pdf (641.91 kB)
Probing BRD inhibition substituent effects in bulky analogues of (+)-JQ1
journal contribution
posted on 2023-06-09, 23:01 authored by Storm Hassell-HartStorm Hassell-Hart, Sarah Picaud, Raphael Lengacher, Joshua Csucker, Regis Millet, Gilles Gasser, Roger Alberto, Hannah Maple, Robert Felix, Zbigniew J Lesnikowski, Helen Stewart, Timothy ChevassutTimothy Chevassut, Simon Morley, Panagis Filippakopoulos, John SpencerJohn SpencerA series of bulky organometallic and organic analogues of the bromodomain (BRD) inhibitor (+)-JQ1 have been prepared. The most potent, N-[(adamantan-1-yl)methyl]-2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamide, 2e, showed excellent potency with an KD=ca. 130 nm vs. BRD4(1) and a ca. 2-fold selectivity over BRD4(2) (KD=ca. 260 nm). Its binding to the first bromodomain of BRD4 was determined by a protein cocrystal structure.
Funding
Poised Fragment Libraries for Atypical Bromodomain Inhibition; G2210; EPSRC-ENGINEERING & PHYSICAL SCIENCES RESEARCH COUNCIL; EP/P026990/1
History
Publication status
- Published
File Version
- Accepted version
Journal
Helvetica Chimica ActaISSN
0018-019XPublisher
WileyExternal DOI
Issue
3Volume
104Page range
1-7Article number
a2000214Department affiliated with
- Clinical and Experimental Medicine Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2021-02-11First Open Access (FOA) Date
2022-01-28First Compliant Deposit (FCD) Date
2021-02-11Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC